Pharmaceutical Manufacturing in China - Industry Market Research Report

Pharmaceutical Manufacturing in China

Revenue for the Pharmaceutical Manufacturing industry is expected to grow at an annualized 1.6% over the five years through 2023, to total $191.7 billion, up 3.2% from 2022. The COVID-19 outbreak contributed to growth in domestic demand for medicine and medical supplies, benefiting the development of the Pharmaceutical Manufacturing industry. The industry's profitability has decreased from 13.7% of industry revenue in 2018 to 13.4% in 2023. An estimated 1,632 industry enterprises operate in 2023, employing about 724,877 people, with a total wage cost of $12.6 billion.

The industry primarily manufactures chemical medicinal and pharmaceutical products in various formats, including ampoules, tablets, capsules, vials, ointments, powders, solutions, suspensions and radioactive medicine. These products are then sold through pharmacies or used in hospitals. Biological and veterinary medicine products are not included in the industry.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.